Author response for "A Twelve‐Week, Randomized, Double‐Blind, Placebo‐Controlled, Four‐Arm Dose‐Finding Phase 2 Study Evaluating Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes"